

# Survey results:

'Have your say on availability of a treatment for patients with platinum resistance'



## Survey overview

We are incredibly grateful to everyone from the Ovacome community who responded to our survey: 'Have your say on availability of a treatment for patients with platinum resistance' between 19 December 2025 and 16 January 2026.

145 people responded, giving invaluable insight into the impact of chemotherapy side effects and helping policy makers to understand patient views on access to treatment options when people become platinum resistant.

At the time of responding, many participants were undergoing treatment and choosing to spend time with family alongside their health needs. From our perspective, this therefore represents a meaningful sample size. Ovacome has approximately 5,600 members affected by ovarian cancer, however, many people who aren't members access our services anonymously. The survey was promoted to both members and the wider community who engage with our services. Responses are therefore likely to reflect a broad range of experiences, including from individuals who may not usually participate in research or feel confident self-advocating.

Those who did not have access treatment at the point of platinum resistance, such as family members who had a relative die of ovarian cancer prior to Mirvetuximab Soravtansine availability through trial or compassionate access, were also able to respond.

To ensure accessibility, respondents were able to access the survey through calls with our support team, where interpreters or translators were available.

# Key focus

---

The National Institute for clinical excellence (NICE) are considering whether the NHS should fund some treatments for those with platinum resistant disease at the moment. Ovacom attends NICE meetings to represent the views of people affected by ovarian cancer.

**In this survey we wanted to ensure that your views and experiences were given to policy makers and NICE, specifically on:**

- The impact of chemotherapy on people's quality of life. Chemotherapy is often still offered when people become platinum resistant.
- The impact of Mirvetuximab Soravtansine on people's quality of life. Mirvetuximab Soravtansine is a new treatment that is effective for some people when they become platinum resistant. NICE are considering whether this treatment can be funded by NHS England.

**The feedback gathered from our community has focused mainly on:**

- The day to day and long-term side effects of chemotherapy and their severity.
- The views expressed by members of our community as to the availability of treatments for ovarian cancer at the later stages of disease, specifically platinum resistance.
- Their opinions as to availability of treatments at point of platinum resistance, specifically relating to Mirvetuximab Soravtansine.

# Findings

---

Because Mirvetuximab Soravtansine has not been widely available to this community, few people are able to directly compare its side effects with chemotherapy. However, feedback from this survey and our broader community indicates that both the treatment frequency of Mirvetuximab Soravtansine (3 weekly versus often weekly for chemotherapy) and the side effect profile are viewed favourably by many of those who have had the opportunity to use it.


A significant majority of responses noted that side effects were both fewer and more manageable than those associated with chemotherapy. This is especially important at this stage of disease as many people would prefer to prioritise spending time with family and friends and doing things that bring them comfort and happiness.

# Respondent profile

- Answered: 145
- I am having chemotherapy for ovarian cancer: 26.21%
- I am a healthcare professional working with ovarian cancer patients: 3.45%
- I have been diagnosed with ovarian cancer: 66.90%
- I have platinum-resistant ovarian cancer: 26.90%
- I have taken Mirvetuximab Soravtansine (Elahere): 4.14%
- I am a family member or friend of someone with ovarian cancer: 11.03%
- Other: 7.59%


## Results

1. Please tell us about the side effects of chemotherapy with regard to your mobility (was it easy to walk around or move?) [94 responses]




2. Please tell us about any side effects of chemotherapy with regard to self care


***(did it affect your ability to look after yourself)? [94 responses]***



***3. Please tell us about any side effects of chemotherapy with regard to you doing the things that are important to you. We mean every day things like time with friends and family, work, study or leisure activities. [93 responses]***



***4. Please tell us about any pain or discomfort you experienced as a result of chemotherapy. [91 responses]***



**5. Please tell us about any anxiety or depression you experienced as a result of chemotherapy. [94 responses]**

